Heparin sodium - instructions for use, dose, side effects, contraindications

Anticoagulant of direct action, strengthens blockade of antithrombin activated III factors of blood coagulation, inactivates factor Xa, inhibits coagulation and formation of a blood clot. Accelerates the formation of complexes of thrombin with antithrombin III, slowing the transformation of fibrinogen into fibrin and the organization of a thrombus. Reduces the aggregation of platelets.

Pharmacokinetics:

After subcutaneous administration, the maximum concentration in the blood plasma is reached after 3-4 hours.

Partially destroyed by heparinase. It does not penetrate the blood-brain and placental barriers.

The half-life is 30-60 minutes. Elimination of the kidneys unchanged.

Indications:

It is used to treat and prevent deep vein thrombosis, pulmonary embolism, coronary artery thrombosis, thrombophlebitis, unstable angina,acute myocardial infarction, atrial fibrillation, DIC syndrome, microcirculatory disorders, renal vein thrombosis, mitral heart disease, bacterial endocarditis, lupus nephritis, glomerulonephritis.

It is used to prevent blood clotting in operations using extracorporeal circulatory methods, hemosorption, hemodialysis, cytapheresis, peritoneal dialysis, forced diuresis, for venous catheter rinsing.

It is used to prepare samples of non-stopping blood for laboratory purposes and blood transfusion.

ICD-10

III.D65-D69.D65 Disseminated intravascular coagulation [defibrillation syndrome]

IX.I20-I25.I21 Acute myocardial infarction

IX.I70-I79.I74 Embolism and thrombosis of the arteries

IX.I70-I79.I77.1 Arterial narrowing

IX.I80-I89.I80 Phlebitis and thrombophlebitis

IX.I80-I89.I82 Embolism and thrombosis of other veins

IX.I80-I89.I83 Varicose veins

XIII.M70-M79.M77.9 Other specified intesopathy

XIX.T08-T14.T14.0 Superficial injury of unspecified area of the body

XIX.T08-T14.T14.9 Injury, unspecified

IX.I20-I25.I20.0 Unstable angina

IX.I26-I28.I26 Pulmonary embolism

IX.I30-I52.I33 Acute and subacute endocarditis

XIV.N00-N08.N00 Acute nephritic syndrome

XIV.N00-N08.N03 Chronic nephritic syndrome

Contraindications:

Conditions and diseases, accompanied by a decrease in blood clotting: thrombocytopenia, a deficiency of coagulation factors, hemorrhagic diathesis. Gastric and duodenal ulcers, acute bacterial endocarditis, hemorrhagic stroke, ulcerative colitis, individual intolerance.

Carefully:

Renal and hepatic insufficiency.

Pregnancy and lactation:

Recommendations for FDA - Category C. Applies to pregnancy and during lactation in cases where the potential benefit from the drug exceeds the possible risk to the fetus and the baby.

Dosing and Administration:

Intravenously, subcutaneously, externally. Dosage is calculated individually, depending on the age, weight and clinical picture of the disease.

Side effects:

Central and peripheral nervous system: dizziness, headache.

The system of hematopoiesis: thrombocytopenia.

Digestive system: anorexia, nausea, vomiting, diarrhea.

Musculoskeletal system: osteoporosis, calcification of soft tissues.

Dermatological reactions: alopecia with prolonged use.

Allergic reactions.

Overdose:

Bleeding.

Treatment is symptomatic.

Interaction:

The risk of bleeding increases with simultaneous use with salicylates, indirect coagulants, glucocorticoids, nonsteroidal anti-inflammatory drugs, antiaggregants.

Special instructions:

Monitoring the number of platelets of peripheral blood, clotting time.

Instructions

Sodium Heparin (Heparinum natrium)